HR in NYC is working on the cut list. No position is safe unless it was part of the deal. Pfizer oncology is already over staffed so likely any redundancies are first to go. Clinical, regulatory, contracts and budgets, data management, sales and legal are all early targets.
It most certainly is, bury your head in the sand all you want, won't stop it from happening. Pfizer has a model for these take-overs, just look at recent history.
I think we should let the true oncology reps ( those that sell Eliquis) be the lead. Nothing like a total cluster with 7-10 reps all concerned with reach and frequency thrown at an overwhelmed group of specialists. Thank goodness drugs for many different types of cancer can bow down to the true driver of hematology/oncology.....Eliquis
Believe me when I tell you that we in C2 don't want to be in there either. We are already spread too thin with Cards, Vascular surgeons & Pulms in huge territories. Little data on cancer patients with limited ROI vs other specialties. If going to sell Eliquis in these offices give to IS. The only product in their bag and limited access in hospitals.
You obviously never worked anywhere else. Pfizer Oncology is closer to a skeleton crew than being over-staffed.
Well....is it a skeleton crew because there's very little to do, or is the skeleton crew overworked? If it's the former, then take the projects/products, kick Medivation staff to the curb, and now oncology people have work. If it's the latter, retaining Medivation staff to augment their numbers and equalize workload seems practical.
